EU and US could reach trade deal this weekend - Reuters
On Monday, RBC Capital Markets reiterated their positive stance on ConvaTec Group Plc (CTEC:LN) (OTC: CNVVY), maintaining an Outperform rating and a price target of GBP3.05. The firm’s analysis suggests a favorable outlook for the company, following an update on its InnovaMatrix product. The medical technology company, currently valued at $7 billion, has demonstrated strong financial health with a "GREAT" overall score according to InvestingPro analysis, supported by robust revenue of $2.29 billion in the last twelve months. ConvaTec estimates that a delay in the implementation of this product will contribute an additional $25 million to its revenue in 2025, which represents about 1% of the group’s total revenue.
The high gross margin nature of InnovaMatrix is expected to support the overall gross margin of the group for the fiscal year 2025. The delay also shortens the potential period during which InnovaMatrix could lack coverage, from an initial range of 12-24 months down to 6-18 months. This adjustment is seen as a positive development for the product’s sales outlook.
ConvaTec’s randomized clinical trials (RCTs) are set to complete in 2026. If the Centers for Medicare & Medicaid Services (CMS) considers real-world evidence in their final draft, InnovaMatrix sales could see further benefits in 2026. This anticipation builds on the already positive forecast for the product’s performance in the market.
The unchanged guidance for other aspects of ConvaTec’s business, despite the delay in InnovaMatrix’s implementation, indicates stability in the company’s operations. RBC Capital’s reaffirmation of their Outperform rating reflects confidence in ConvaTec’s ability to navigate this delay and capitalize on the potential of InnovaMatrix to enhance its financial performance in the coming years. The company’s stock has demonstrated low volatility and has gained 12.51% year-to-date, suggesting investor confidence in its strategic direction.
In other recent news, Convatec Group PLC has seen its outlook upgraded to positive by Moody’s Ratings. This change comes as Moody’s affirmed the company’s Ba1 long-term corporate family rating and Ba1-PD probability of default rating. The upgrade is attributed to Convatec’s solid organic revenue and margin growth, backed by a successful transformation program and a strong product pipeline that exceeded the company’s 2024 guidance. Convatec’s focus on the chronic care market, which ensures recurring revenue, also played a role in the positive rating action.
Additionally, the company has maintained a conservative financial policy with a net leverage target of around 2x, and Moody’s expects its adjusted gross debt to EBITDA to remain below 2.5x over the next 12-18 months. Convatec’s transformation program has addressed historical operational issues, resulting in improved organic growth and margin expansion. Moody’s notes that Convatec’s good liquidity, including a cash balance of $65 million and significant availability under its revolving credit facility, supports its financial stability. The positive outlook reflects expectations of continued revenue growth and margin expansion, coupled with successful productivity and simplification initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.